Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

SLC6A14 and SLC38A5 Drive the Glutaminolysis and Serine–Glycine–One-Carbon Pathways in Cancer

Pharmaceuticals(2021)10.3390/ph14030216Source: DataRank Database

SLC6A14 and SLC38A5 Drive the Glutaminolysis and Serine–Glycine–One-Carbon Pathways in Cancer is a research paper published in Pharmaceuticals (2021). On theSindex it has a DataRank of 0. It has been cited 81 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access81 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: goldTopics (13)Linked Datasets (6)DataCite Reuse (6)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Ksenija Korać,Yangzom D. Bhutia ORCID,Vadivel Ganapathy ORCID,Tyler Sniegowski

Live enrichment

PubMed:33806675 PMC:PMC8000594

Welch Endowed Chair in Biochemistry

Grant: BI-0028

National Institutes of Health

Grant: CA223271

NCI NIH HHS

Grant: R03 CA223271

National Institutes of Health

Grant: 1R03CA223271-01A1

Carbidopa as an inhibitor of the TrpT/ID01 functional complex: A novel immunotherapy agent

goldLicense: cc-by

publisherhttps://www.mdpi.com/1424-8247/14/3/216/pdf?version=1614943275

publisherhttps://www.mdpi.com/1424-8247/14/3/216/pdf

repositoryhttps://doaj.org/article/725d0d05fe9b460a8e91b59cf07aff2e

repositoryhttps://dx.doi.org/10.3390/ph14030216

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8000594

Fields of Study

0301 basic medicine03 medical and health sciences

Keywords

Amino Acid TransportersOncometabolitesOne-carbon MetabolismGlutamine AddictionCancer-specific MetabolismSlc6a14 And Slc38a5RReviewRS1-441Pharmacy and materia medicaMedicine

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Metabolic subtypes and immune landscapes in esophageal squamous cell carcinoma: prognostic implications and potential for personalized therapies

10.6084/m9.figshare.25248811.v1figshare

Additional file 1 of Metabolic subtypes and immune landscapes in esophageal squamous cell carcinoma: prognostic implications and potential for personalized therapies

10.6084/m9.figshare.25248811figshare

Additional file 2 of Metabolic subtypes and immune landscapes in esophageal squamous cell carcinoma: prognostic implications and potential for personalized therapies

10.6084/m9.figshare.25248919.v1figshare

Additional file 2 of Metabolic subtypes and immune landscapes in esophageal squamous cell carcinoma: prognostic implications and potential for personalized therapies

10.6084/m9.figshare.25248919figshare

Additional file 3 of Metabolic subtypes and immune landscapes in esophageal squamous cell carcinoma: prognostic implications and potential for personalized therapies

10.6084/m9.figshare.26682571.v1figshare

Additional file 3 of Metabolic subtypes and immune landscapes in esophageal squamous cell carcinoma: prognostic implications and potential for personalized therapies

10.6084/m9.figshare.26682571figshare